請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64071完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 吳亘承(Hsuan-Chen Wu) | |
| dc.contributor.author | Ying-Chih Kung | en |
| dc.contributor.author | 龔穎之 | zh_TW |
| dc.date.accessioned | 2021-06-16T17:28:48Z | - |
| dc.date.available | 2021-02-22 | |
| dc.date.copyright | 2021-02-22 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-02-04 | |
| dc.identifier.citation | 1. Hanahan, D. and Weinberg R., Hallmarks of Cancer: The Next Generation. Cell, 2011. 144(5): p. 646-674. 2. Swann, J.B. and M.J. Smyth, Immune surveillance of tumors. Journal of Clinical Investigation, 2007. 117(5): p. 1137-1146. 3. Gerber, D.E., Targeted therapies: a new generation of cancer treatments. American Family Physician, 2008. 77(3): p. 311-319. 4. Serrano, P., et al., Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clinical Pharmacology and Therapeutics, 2019. 105(3): p. 582-597. 5. Ishida, Y., et al., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO Journal, 1992. 11(11): p. 3887-3895. 6. Leach, D.R., M.F. Krummel, and J.P. Allison, Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science, 1996. 271(5256): p. 1734-1736. 7. Hodi, F.S., et al., Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 2010. 363(8): p. 711-723. 8. Brahmer, J.R., et al., Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology, 2010. 28(19): p. 3167-3175. 9. Turley, S.J., V. Cremasco, and J.L. Astarita, Immunological hallmarks of stromal cells in the tumour microenvironment. Nature Reviews Immunology, 2015. 15(11): p. 669-682. 10. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nature reviews. Cancer, 2012. 12(4): p. 252-264. 11. Sun, Z., et al., IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Research, 2015. 75(8): p. 1635-1644. 12. Thibult, M.-L., et al., PD-1 is a novel regulator of human B-cell activation. International Immunology, 2013. 25(2): p. 129-137. 13. Francisco, L.M., P.T. Sage, and A.H. Sharpe, The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews, 2010. 236(1): p. 219-242. 14. Poggio, M., et al., Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell, 2019. 177(2): p. 414-427. 15. Kümpers, C., et al., Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. Frontiers in Medicine, 2019. 6(27). 16. Liu, Y.-H., et al., Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomedicine and Pharmacotherapy, 2019. 120: p. 109437-109443. 17. Kellner, C., et al., Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy. Transfusion Medicine and Hemotherapy, 2017. 44(5): p. 327-336. 18. Bajwa, R., et al., Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study. Journal of Clinical Medicine Research, 2019. 11(4): p. 225-236. 19. Michot, J.M., et al., Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer, 2016. 54: p. 139-148. 20. Chupak, L.S., et al., Compounds useful as immunomodulators. 2017, Google Patents. 21. Zhang, F., et al., Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discovery, 2017. 3(1): p. 17004-17016. 22. Chang, H.-N., et al., Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy. Angewandte Chemie International Edition, 2015. 54(40): p. 11760-11764. 23. Lee, J.J., et al., Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas. Journal of Clinical Oncology, 2017. 35(15_suppl): p. TPS3099-TPS3099. 24. Shimizu, T., et al., Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors. Journal of Clinical Oncology, 2019. 37(15_suppl): p. 2609-2609. 25. Marin-Acevedo, J.A., et al., Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology Oncology, 2018. 11(1): p. 39-59. 26. Mengesha, A., et al., Potential and limitations of bacterial-mediated cancer therapy. Frontiers in Bioscience, 2007. 12: p. 3880-3891. 27. Forbes, N.S., Engineering the perfect (bacterial) cancer therapy. Nature Reviews Cancer, 2010. 10(11): p. 785-794. 28. Gardlik, R., et al., Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene therapy, 2011. 18(5): p. 425-431. 29. Leschner, S., et al., Tumor Invasion of Salmonella enterica Serovar Typhimurium Is Accompanied by Strong Hemorrhage Promoted by TNF-α. PLoS One, 2009. 4(8): p. e6692. 30. Kasinskas, R.W. and N.S. Forbes, Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnology and Bioengineering, 2006. 94(4): p. 710-721. 31. Kasinskas, R.W. and N.S. Forbes, Salmonella typhimurium Lacking Ribose Chemoreceptors Localize in Tumor Quiescence and Induce Apoptosis. Cancer Research, 2007. 67(7): p. 3201-3209. 32. Felgner, S., et al., Bacteria in Cancer Therapy: Renaissance of an Old Concept. International Journal of Microbiology, 2016. 2016: p. 1-14. 33. Felgner, S., et al., Engineered Salmonella enterica serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor therapy. OncoImmunology, 2018. 7(2): p. e1382791. 34. Westphal, K., et al., Containment of Tumor-Colonizing Bacteria by Host Neutrophils. Cancer Research, 2008. 68(8): p. 2952-2960. 35. Lee, C.-H., C.-L. Wu, and A.-L. Shiau, Endostatin gene therapy delivered bySalmonella choleraesuis in murine tumor models. The Journal of Gene Medicine, 2004. 6(12): p. 1382-1393. 36. Agorio, C., et al., Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. The Journal of Gene Medicine, 2007. 9(5): p. 416-423. 37. Yang, N., et al., Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic. Cancer Biology and Therapy, 2008. 7(1): p. 145-151. 38. Jiang, S.-N., et al., Inhibition of Tumor Growth and Metastasis by a Combination of Escherichia coli–mediated Cytolytic Therapy and Radiotherapy. Molecular Therapy, 2010. 18(3): p. 635-642. 39. He, L., et al., Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy. Journal of Biological Engineering, 2019. 13(1): p.58-71. 40. Zheng, J.H., et al., Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Science Translational Medicine, 2017. 9(376): p. eaak9537. 41. Gurbatri, C., et al., Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Science Translational Medicine, 2020. 12(530): p. eaax0876.. 42. Nemunaitis, J., et al., Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Therapy, 2003. 10(10): p. 737-744. 43. Stritzker, J., et al., Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. International Journal of Medical Microbiology, 2007. 297(3): p. 151-162. 44. Matsumoto, M., et al., Longevity in Mice Is Promoted by Probiotic-Induced Suppression of Colonic Senescence Dependent on Upregulation of Gut Bacterial Polyamine Production. PLoS ONE, 2011. 6(8): p. e23652. 45. Duong, M.T.-Q., et al., Bacteria-cancer interactions: bacteria-based cancer therapy. Experimental and Molecular Medicine, 2019. 51(12): p. 152-167. 46. Sonnenborn, U., Escherichia coli strain Nissle 1917—from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiology Letters, 2016. 363(19): p. fnw212. 47. Reister, M., et al., Complete genome sequence of the Gram-negative probiotic Escherichia coli strain Nissle 1917. Journal of Biotechnology, 2014. 187: p. 106-107. 48. Azpiroz, M.a.F., E. Rodrı́guez, and M. Laviña, The Structure, Function, and Origin of the Microcin H47 ATP-Binding Cassette Exporter Indicate Its Relatedness to That of Colicin V. Antimicrobial Agents and Chemotherapy, 2001. 45(3): p. 969-972. 49. Nougayrede, J.P., Escherichia coli Induces DNA Double-Strand Breaks in Eukaryotic Cells. Science, 2006. 313(5788): p. 848-851. 50. Homburg, S., et al., Expression analysis of the colibactin gene cluster coding for a novel polyketide inEscherichia coli. FEMS Microbiology Letters, 2007. 275(2): p. 255-262. 51. Schroder, K., et al., Interferon-γ: an overview of signals, mechanisms and functions. Journal of Leukocyte Biology, 2004. 75(2): p. 163-189. 52. Wu, L., Recognition of Host Immune Activation by Pseudomonas aeruginosa. Science, 2005. 309(5735): p. 774-777. 53. Wang, Y., The Function of OmpA in Escherichia coli. Biochemical and Biophysical Research Communications, 2002. 292(2): p. 396-401. 54. Verhoeven, G.S., et al., Differential Bacterial Surface Display of Peptides by the Transmembrane Domain of OmpA. PLoS ONE, 2009. 4(8): p. e6739. 55. Aurand, T.C. and J.C. March, Development of a synthetic receptor protein for sensing inflammatory mediators interferon-γ and tumor necrosis factor-α. Biotechnology and Bioengineering, 2016. 113(3): p. 492-500. 56. Butte, M.J., et al., Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. Immunity, 2007. 27(1): p. 111-122. 57. Butte, M.J., et al., Interaction of human PD-L1 and B7-1. Molecular Immunology, 2008. 45(13): p. 3567-3572. 58. Cheng, X., et al., Structure and Interactions of the Human Programmed Cell Death 1 Receptor. Journal of Biological Chemistry, 2013. 288(17): p. 11771-11785. 59. Ghiotto, M., et al., PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. International Immunology, 2010. 22(8): p. 651-660. 60. Lázár-Molnár, E., et al., Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine, 2017. 17: p. 30-44. 61. Lee, J.-R., et al., Magneto-nanosensor platform for probing low-affinity protein–protein interactions and identification of a low-affinity PD-L1/PD-L2 interaction. Nature Communications, 2016. 7: p. 12220-12229. 62. Magnez, R., et al., PD-1/PD-L1 binding studies using microscale thermophoresis. Scientific Reports, 2017. 7(17623). 63. Tan, S., et al., An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nature Communications, 2017. 8(1): p. 14369-14379. 64. Youngnak, P., et al., Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochemical and Biophysical Research Communications, 2003. 307(3): p. 672-677. 65. Li, C., et al., Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunology Research, 2018. 6(2): p. 178-188. 66. Kotzsch, A., et al., A secretory system for bacterial production of high-profile protein targets. Protein Science, 2011. 20(3): p. 597-609. 67. Jarmander, J., et al., A dual tag system for facilitated detection of surface expressed proteins in Escherichia coli. Microbial Cell Factories, 2012. 11(1): p. 118-128. 68. Tsao, C.-Y., et al., Autonomous induction of recombinant proteins by minimally rewiring native quorum sensing regulon of E. coli. Metabolic Engineering, 2010. 12(3): p. 291-297. 69. Wu, H.C., et al., Autonomous bacterial localization and gene expression based on nearby cell receptor density. Molecular Systems Biology, 2014. 9(1): p. 636-636. 70. Zhou, K., et al., Novel reference genes for quantifying transcriptional responses of Escherichia coli to protein overexpression by quantitative PCR. BMC Molecular Biology, 2011. 12(1): p. 18-27. 71. Zheng, Y., Y.C. Fang, and J. Li, PD‑L1 expression levels on tumor cells affect their immunosuppressive activity. Oncology Letters, 2019. 18(5): p. 5399–5407. 72. Bury, S., et al., The Probiotic Escherichia coli Strain Nissle 1917 Combats Lambdoid Bacteriophages stx and λ. Frontiers in Microbiology, 2018. 9(929). 73. Kurtz, C., et al., Translational Development of Microbiome-Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates. Clinical and Translational Science, 2018. 11(2): p. 200-207. 74. Weiner, L., J.L. Brissette, and P. Model, Stress-induced expression of the Escherichia coli phage shock protein operon is dependent on sigma 54 and modulated by positive and negative feedback mechanisms. Genes and Development, 1991. 5(10): p. 1912-1923. 75. Burdette, L.A., et al., Developing Gram-negative bacteria for the secretion of heterologous proteins. Microbial Cell Factories, 2018. 17(1): p.196-222. 76. Flores-Kim, J. and A.J. Darwin, The Phage Shock Protein Response. Annual Review of Microbiology, 2016. 70(1): p. 83-101. 77. Gibson, D.G., et al., Enzymatic assembly of DNA molecules up to several hundred kilobases. Nature Methods, 2009. 6(5): p.343-345. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64071 | - |
| dc.description.abstract | 免疫檢查點抑制法 (immune checkpoint inhibition) 是現今癌症免疫治療中具有發展潛力的療法，其可反轉癌細胞經由免疫檢查點抑制T細胞活化之過程，進而激活免疫系統消除癌細胞。然而免疫檢查點抑制法仍有許多限制，例如：(1) 抑制劑藥物為大分子蛋白質或抗體，無法有效地深入固體腫瘤深處；(2) 免疫功能過度激活導致全身性自體免疫疾病。因此，如何有效地將免疫檢查點抑制藥物運送至腫瘤微環境是一個待克服的問題。在本研究中，我們利用基因工程改造的微生物載體作為免疫檢查點抑制劑的傳輸系統，以增進免疫檢查點抑制法的成效。我們希望以合成生物學之方法建構出具有 (1) 辨認腫瘤微環境中的免疫調控訊息interferon γ (IFN-γ) 的能力與 (2) 受IFN-γ偵測訊號調控免疫檢查點抑制劑的生合成之腸道益生菌 E. coli Nissle 1917 (EcN)。我們成功讓微生物生產並外泌出免疫檢查點抑制劑，且抑制劑在濃度約52 μM的情形下，能夠有效地與癌細胞表面上的免疫檢查點蛋白質結合。然而，我們目前建構的IFN-γ感測系統尚無法有效開啟下游目標基因，推測可能是IFN-γ產生的壓力訊號不足，仍需更進一步探討與調整基因迴路以達到偵測效果。綜合來說，本研究所建構的微生物載體系統能外泌免疫檢查點抑制劑藥物，利用合成生物學的優勢，未來能與其他技術合併，幫助新一代抗癌藥物的發展。 | zh_TW |
| dc.description.abstract | Immune checkpoint inhibition has great potential for development in cancer immunotherapy nowadays. Immune checkpoint inhibitors revert the T cell inhibitory signaling generated by cancer cells through immune checkpoint pathway and reactivated subsequent anti-tumor immune response. Still, there are some concerns in immune checkpoint inhibition therapy. For example, inhibitors like antibodies could hardly penetrate into the core of solid tumors. Also, uncontrolled activation of the immune system causes systematic immune-related adverse events, like cytokine release syndrome (CRS). Therefore, how to effectively deliver immune checkpoint inhibitors to tumor microenvironments remains a big challenge. With the intrinsic anti-tumor property of anaerobic bacteria, bacteria-mediated tumor therapy (BMTT) has made tremendous progress in cancer therapeutic studies recently. In this research, we utilize genetically engineered microorganisms as drug delivery vectors to enhance the efficiency of immune checkpoint inhibition therapy. With the strategy of synthetic biology, we aim to engineer a novel probiotic vehicle with the ability of sensing interferon γ (IFN-γ), a signaling cytokine released by the immune system against tumors, and synthesizing a common immune checkpoint inhibitor, PDL1 blocker, upon sensing the immune systems in the tumor microenvironments. We successfully modified the probiotic E. coli strain Nissle 1917 (EcN) to produce and secrete out anti-PDL1 peptide, TPP. TPP peptide effectively blocked immune checkpoint protein on surface of tumor cells at the concentration of 52 μM. However, the IFN-γ sensing system currently constructed in the research briefly showed no significant detection ability. More characterizations and genetic circuit reprogramming will be implemented to tune up the sensing capability. In summary, we successfully constructed the secretory system of immune checkpoint inhibitor in bacteria. We envision this system is able to be integrated with other synthetic biology modalities developing a new generation anti-cancer therapy in the future. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T17:28:48Z (GMT). No. of bitstreams: 1 U0001-0202202118405200.pdf: 2232507 bytes, checksum: 8da48f6405cb6b0bc1572d0ef6aeb7d4 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 誌謝 i 中文摘要 ii 英文摘要 iii 第1章 緒論 1 1.1. 癌症治療方法 1 1.1.1. 癌症與腫瘤微環境的簡介 1 1.1.2. 現行癌症治療法 2 1.1.3. 免疫檢查點抑制劑療法 2 1.1.3.1. 免疫檢查點的作用機制 3 1.1.3.2. 免疫檢查點抑制劑療法的副作用與限制 4 1.1.3.3. 免疫檢查點抑制劑現今的發展 5 1.1.4. 細菌療法 6 1.1.4.1. 細菌療法的機制 6 1.1.4.2. 細菌療法的副作用與限制 7 1.1.4.3. 細菌療法現今的發展 8 1.1.4.4. 益生菌Nissle 1917 9 1.2. 細菌的IFN-γ感測系統 10 1.2.1. IFN-γ的簡介 10 1.2.2. 綠膿桿菌的OprF 蛋白質 10 1.2.3. OmpA/OprF 嵌合蛋白質 11 1.3. 研究動機 12 1.3.1. 目的 12 1.3.2. 策略 12 1.3.3. 欲達成之目標 15 第2章 材料與方法 18 2.1. 實驗菌株與培養條件 18 2.1.1. 細菌 18 2.1.2. 細胞株 18 2.2. 培養基與藥品 19 2.3. 表現載體之建構 20 2.3.1. pSC101-OmpA/OprF 20 2.3.2. pBAC-PpspA-T7Rpol 20 2.3.3. pET200-T7P-OsmY-6xHis-TPP (or SPP) 20 2.3.4. pET200-T7P-OsmY-6xHis-mCherry-TPP (or SPP) 21 2.3.5. pET200-TPP (or SPP)-Venus-AIDA-I 21 2.4. 大腸桿菌電穿孔轉形法 25 2.4.1. E. coli勝任細胞製備 25 2.4.2. 電穿孔轉形 25 2.5. 免疫檢查點抑制劑之分析 26 2.5.1. 聚丙烯醯胺膠體電泳分析 26 2.5.2. 西方墨點法 26 2.5.3. 蛋白質純化與濃縮 26 2.5.4. 超微薄膜過濾法濃縮 27 2.5.5. 外泌之免疫檢查點抑制劑功能性測試 27 2.5.6. 表面呈現之免疫檢查點抑制劑功能性測試 27 2.6. IFN-γ感測系統之分析 29 2.6.1. IFN-γ感測系統之功能檢測 29 2.6.2. T7Rpol mRNA分析 29 第3章 結果 32 3.1. 免疫檢查點抑制劑活性測試 32 3.1.1. 構築外泌型免疫檢查點抑制劑表現菌株 32 3.1.2. 蛋白質表現與純化 34 3.1.3. 外泌型免疫檢查點抑制劑活性測試 39 3.1.4. 表面呈現之免疫檢查點抑制劑功能性測試 43 3.2. 大腸桿菌IFN-γ感測系統之改良 48 3.2.1. 於Nissle 1917中構築IFN-γ感測系統 48 3.2.2. IFN-γ感測系統之活性測試 50 3.2.3. 誘導後不同時間點之T7Rpol表現量分析 51 第4章 討論 53 4.1. OsmY嵌合蛋白質外泌系統 53 4.2. TPP免疫檢查點抑制劑的活性測試 53 4.3. 表面呈現免疫檢查點抑制劑系統 54 4.4. IFN-γ感測系統 54 第5章 結論 56 第6章 未來展望 57 第7章 參考資料 58 | |
| dc.language.iso | zh-TW | |
| dc.subject | 癌症免疫療法 | zh_TW |
| dc.subject | Nissle 1917 | zh_TW |
| dc.subject | 細菌療法 | zh_TW |
| dc.subject | IFN-γ | zh_TW |
| dc.subject | 免疫檢查點 | zh_TW |
| dc.subject | BMTT | en |
| dc.subject | cancer immunotherapy | en |
| dc.subject | EcN | en |
| dc.subject | immune checkpoint | en |
| dc.subject | IFN-γ | en |
| dc.title | 基因轉殖大腸桿菌具有感測腫瘤微環境暨藥物輸送能力之探討分析 | zh_TW |
| dc.title | Evaluation of Engineered Escherichia coli as a Tumor Sensing and Drug Delivery Device for Enhancing Tumor Immunotherapy | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 109-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 楊啓伸(Chii-Shen Yang),黃筱鈞(Hsiao-Chun Huang) | |
| dc.subject.keyword | 癌症免疫療法,免疫檢查點,IFN-γ,細菌療法,Nissle 1917, | zh_TW |
| dc.subject.keyword | cancer immunotherapy,immune checkpoint,IFN-γ,BMTT,EcN, | en |
| dc.relation.page | 63 | |
| dc.identifier.doi | 10.6342/NTU202100409 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2021-02-05 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科技學系 | zh_TW |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0202202118405200.pdf 未授權公開取用 | 2.18 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。